Publicaciones en colaboración con investigadores/as de University of Oxford (74)

2024

  1. AI is a viable alternative to high throughput screening: a 318-target study

    Scientific Reports, Vol. 14, Núm. 1

  2. An atlas of cells in the human tonsil

    Immunity, Vol. 57, Núm. 2, pp. 379-399.e18

  3. CD137 (4-1BB) and T-Lymphocyte Exhaustion

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 3971-3973

  4. Correction to: AI is a viable alternative to high throughput screening: a 318-target study (Scientific Reports, (2024), 14, 1, (7526), 10.1038/s41598-024-54655-z)

    Scientific Reports

  5. Costs-effectiveness and cost components of pharmaceutical and non-pharmaceutical interventions affecting antibiotic resistance outcomes in hospital patients: a systematic literature review

    BMJ Global Health, Vol. 9, Núm. 2

  6. Cytotoxicity as a form of immunogenic cell death leading to efficient tumor antigen cross-priming

    Immunological Reviews, Vol. 321, Núm. 1, pp. 143-151

  7. Double-Stranded RNA to Mimic Viral Infection for Cancer Immunotherapy

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 16, pp. 3355-3357

  8. Low-Dose Ionizing γ-Radiation Elicits the Extrusion of Neutrophil Extracellular Traps

    Clinical cancer research : an official journal of the American Association for Cancer Research, Vol. 30, Núm. 18, pp. 4131-4142

  9. MHC Hammer reveals genetic and non-genetic HLA disruption in cancer evolution

    Nature Genetics

  10. Meat consumption and incident type 2 diabetes: an individual-participant federated meta-analysis of 1·97 million adults with 100 000 incident cases from 31 cohorts in 20 countries

    The Lancet Diabetes and Endocrinology, Vol. 12, Núm. 9, pp. 619-630

  11. Regional and intratumoral adoptive T-cell therapy

    Immuno-Oncology and Technology, Vol. 24

  12. Short-term cultured tumor fragments to study immunotherapy combinations based on CD137 (4-1BB) agonism

    OncoImmunology, Vol. 13, Núm. 1

  13. Society for Immunotherapy of Cancer (SITC) recommendations on intratumoral immunotherapy clinical trials (IICT): from premalignant to metastatic disease

    Journal for ImmunoTherapy of Cancer, Vol. 12, Núm. 4

  14. Spatially resolved tissue imaging to analyze the tumor immune microenvironment: beyond cell-type densities

    Journal for immunotherapy of cancer, Vol. 12, Núm. 5

  15. The liver as a cytokine factory working on mRNA blueprints for cancer immunotherapy

    Cancer Cell

  16. Tumor slice culture system for ex vivo immunotherapy studies

    Methods in Cell Biology, Vol. 189, pp. 55-69

2023

  1. ATXN3 controls DNA replication and transcription by regulating chromatin structure

    Nucleic acids research, Vol. 51, Núm. 11, pp. 5396-5413

  2. CD137 (4-1BB) requires physically associated cIAPs for signal transduction and antitumor effects

    Science advances, Vol. 9, Núm. 33, pp. eadf6692

  3. Correction: “The 5th edition of The World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms” Leukemia. 2022 Jul;36(7):1720–1748 (Leukemia, (2022), 36, 7, (1720-1748), 10.1038/s41375-022-01620-2)

    Leukemia

  4. Design and methodological considerations for biomarker discovery and validation in the Integrative Analysis of Lung Cancer Etiology and Risk (INTEGRAL) Program

    Annals of Epidemiology, Vol. 77, pp. 1-12